Akebia Therapeutics shares surge 16.62% intraday due to strong Q4 financial results and projected growth in Vafseovadadustat sales.
ByAinvest
Thursday, Feb 26, 2026 9:47 am ET1min read
AKBA--
Akebia Therapeutics surged 16.62% intraday, driven by its Q4 2025 financial results showing $57.62 million in revenue (up 23.9% YoY, exceeding estimates of $48.37 million) and a narrowed net loss of -$12.24 million vs. -$22.8 million in 2024. The company also reported 2025 full-year revenue of $236.2 million (up 47% YoY) and projected significant 2026 growth for its product Vafseovadadustat, supported by expanded dialysis patient coverage (290,000 patients), new patient additions, and improved adherence. Pipeline advancements include ongoing phase II trials for praliciguat and planned phase II trials for AKB-097 in 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet